Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex

Deepak Kumar Bhatt, Abdul Basit, Haeyoung Zhang, Andrea Gaedigk, Seung-Been Lee, Katrina G Claw, Aanchal Mehrotra, Amarjit Singh Chaudhry, Robin E Pearce, Roger Gaedigk, Ulrich Broeckel, Timothy A Thornton, Deborah A Nickerson, Erin G Schuetz, John K Amory, J Steven Leeder, Bhagwat Prasad, Deepak Kumar Bhatt, Abdul Basit, Haeyoung Zhang, Andrea Gaedigk, Seung-Been Lee, Katrina G Claw, Aanchal Mehrotra, Amarjit Singh Chaudhry, Robin E Pearce, Roger Gaedigk, Ulrich Broeckel, Timothy A Thornton, Deborah A Nickerson, Erin G Schuetz, John K Amory, J Steven Leeder, Bhagwat Prasad

Abstract

The major objective of this study was to investigate the association of genetic and nongenetic factors with variability in protein abundance and in vitro activity of the androgen-metabolizing enzyme UGT2B17 in human liver microsomes (n = 455). UGT2B17 abundance was quantified by liquid chromatography-tandem mass spectrometry proteomics, and enzyme activity was determined by using testosterone and dihydrotestosterone as in vitro probe substrates. Genotyping or gene resequencing and mRNA expression were also evaluated. Multivariate analysis was used to test the association of UGT2B17 copy number variation, single nucleotide polymorphisms (SNPs), age, and sex with its mRNA expression, abundance, and activity. UGT2B17 gene copy number and SNPs (rs7436962, rs9996186, rs28374627, and rs4860305) were associated with gene expression, protein levels, and androgen glucuronidation rates in a gene dose-dependent manner. UGT2B17 protein (mean ± S.D. picomoles per milligram of microsomal protein) is sparsely expressed in children younger than 9 years (0.12 ± 0.24 years) but profoundly increases from age 9 years to adults (∼10-fold) with ∼2.6-fold greater abundance in males than in females (1.2 vs. 0.47). Association of androgen glucuronidation with UGT2B15 abundance was observed only in the low UGT2B17 expressers. These data can be used to predict variability in the metabolism of UGT2B17 substrates. Drug companies should include UGT2B17 in early phenotyping assays during drug discovery to avoid late clinical failures.

Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Figures

Fig. 1.
Fig. 1.
The UGT2B17 gene deletion is associated with its protein abundance (A), rates of testosterone- and DHT-glucuronide formation (B and C, respectively). UGT2B17 diplotypes (haplotype pairs on homologous chromosomes) are associated with UGT2B17 mRNA expression (D), protein abundance (E), testosterone-glucuronide formation (F), and DHT-glucuronide formation (G). Confounding factor, that is, samples from subjects aged younger than 12 years, were excluded from the subanalysis. *P < 0.05; **P < 0.01; ***P < 0.0001. Sample number in each group is shown in parentheses in the x-axis.
Fig. 2.
Fig. 2.
Categorical age-dependent UGT2B17 protein abundance (A–D), testosterone (T)-glucuronide formation (E–H), and DHT-glucuronide formation (I–L) data in all (A, E, and I), male (B, F and J) and female (C, G, and K) livers. The x-axis labels identifying data categories in the bottom panel (I–L) are also applicable to the corresponding top two panels (A–H). Number of samples is presented either as main label in the x-axis (A–H) or the x-axis parentheses (I–L). Donors with zero UGT2B17 gene copy were excluded from this analysis. Of 375 samples (male plus female), 205 were lower than the LOD of UGT2B17 protein measurement. For statistical analysis, samples <LOD (excluding zero copy number) were assigned a value of 0.06 pmol/mg of microsomal protein, which was one-third the LLOQ (0.17 pmol/mg of microsomal protein). UGT2B17 was sparsely (12 of 92 samples) detected in children younger than the age of 9 years. An association of age with UGT2B17 abundance or testosterone and DHT-glucuronide formation was more prominent in male versus. female. Mean UGT2B17 protein abundance and testosterone- and DHT-glucuronide formation in these samples was 2.8-, 1.9-, and 1.4-fold greater in male versus female donors aged ≥12 years, respectively (D). *P < 0.05; **P < 0.01; ***P < 0.0001.
Fig. 3.
Fig. 3.
The UGT2B15 SNP (rs1902023) is not associated with UGT2B15 protein abundance in low UGT2B17 expressers (A), but it is significantly associated with increased rates of testosterone-glucuronide (B) and DHT-glucuronide (C) formation (picomoles per milligram per minute microsomal protein). Only samples with UGT2B17 abundance <LOD (0.06 pmol/mg of microsomal protein) samples were included in this analysis.

References

    1. Angstadt AY, Berg A, Zhu J, Miller P, Hartman TJ, Lesko SM, Muscat JE, Lazarus P, Gallagher CJ. (2013) The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk. Cancer 119:2477–2485.
    1. Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M, Kantoff PW, Lee GSM. (2008) Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate 68:839–848.
    1. Barbier O, Bélanger A. (2008) Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 22:259–270.
    1. Beaulieu M, Lévesque E, Hum DW, Bélanger A. (1996) Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem 271:22855–22862.
    1. Bhatt DK, Gaedigk A, Pearce RE, Leeder JS, Prasad B. (2017) Age-dependent protein abundance of cytosolic alcohol and aldehyde dehydrogenases in human liver. Drug Metab Dispos 45:1044–1048.
    1. Bhatt DK, Prasad B. (2018) Critical issues and optimized practices in quantification of protein abundance level to determine inter-individual variability in DMET proteins by LC-MS/MS proteomics. Clin Pharmacol Ther 103:619–630.
    1. Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, Juliusson G, Sutton LA, Mansouri L. (2016) UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? Haematologica 101:e63–e65.
    1. Burgess KS, Philips S, Benson EA, Desta Z, Gaedigk A, Gaedigk R, Segar MW, Liu Y, Skaar TC. (2015) Age-related changes in microRNA expression and pharmacogenes in human liver. Clin Pharmacol Ther 98:205–215.
    1. Chen G, Luo S, Kozlovich S, Lazarus P. (2016a) Association between glucuronidation genotypes and urinary NNAL metabolic phenotypes in smokers. Cancer Epidemiol Biomarkers Prev 25:1175–1184.
    1. Chen SM, Atchley DH, Murphy MA, Gurley BJ, Kamdem LK. (2016b) Impact of UGT2B17 gene deletion on the pharmacokinetics of 17-hydroexemestane in healthy volunteers. J Clin Pharmacol 56:875–884.
    1. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ. (2004) UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656–665.
    1. Du QQ, Wang ZJ, He L, Jiang XH, Wang L. (2013) PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol 69:1917–1925.
    1. Ekström L, Johansson M, Rane A. (2013) Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus. Drug Metab Dispos 41:291–295.
    1. Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC. (2013) Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res 12:4402–4413.
    1. Gallagher CJ, Balliet RM, Sun D, Chen G, Lazarus P. (2010) Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos 38:2204–2209.
    1. Gauthier-Landry L, Bélanger A, Barbier O. (2015) Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution. J Steroid Biochem Mol Biol 145:187–192.
    1. Gordon AS, Fulton RS, Qin X, Mardis ER, Nickerson DA, Scherer S. (2016) PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet Genomics 26:161–168.
    1. Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, Le T, Zehetmayer S, Mannhalter C, Gaiger A, et al. (2013) Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood 121:1175–1183.
    1. Guillemette C. (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136–158.
    1. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, et al. (2008) Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14:3312–3318.
    1. Hirata H, Hinoda Y, Zaman MS, Chen Y, Ueno K, Majid S, Tripsas C, Rubin M, Chen LM, Dahiya R. (2010) Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer. Carcinogenesis 31:1620–1626.
    1. Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treloar J, Giles GG, English DR, Hopper JL, Tilley WD, Mackenzie PI. (2010) A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide. Mol Pharmacol 78:714–722.
    1. Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, et al. (2016) Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Res 76:5881–5893.
    1. Kpoghomou MA, Soatiana JE, Kalembo FW, Bishwajit G, Sheng W. (2013) UGT2B17 polymorphism and risk of prostate cancer: a meta-analysis. ISRN Oncol 2013:465916.
    1. Lazarus P, Zheng Y, Runkle EA, Muscat JE, Wiener D. (2005) Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 15:769–778.
    1. Luo S, Chen G, Truica C, Baird CC, Leitzel K, Lazarus P. (2017) Role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenomics J DOI: [published ahead of print].
    1. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. (2006) Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60:762–769.
    1. Neumann E, Mehboob H, Ramírez J, Mirkov S, Zhang M, Liu W. (2016) Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol 7:437.
    1. Oda S, Fukami T, Yokoi T, Nakajima M. (2015) A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30:30–51.
    1. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T, et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83–92.
    1. Pâquet S, Fazli L, Grosse L, Verreault M, Têtu B, Rennie PS, Bélanger A, Barbier O. (2012) Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression. J Clin Endocrinol Metab 97:E428–E432.
    1. Pearce RE, Gaedigk R, Twist GP, Dai H, Riffel AK, Leeder JS, Gaedigk A. (2016) Developmental expression of CYP2B6: a comprehensive analysis of mRNA expression, protein content and bupropion hydroxylase activity and the impact of genetic variation. Drug Metab Dispos 44:948–958.
    1. Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, Ambudkar SV, Unadkat JD. (2014) Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos 42:78–88.
    1. Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, Chu X, Xiao G, Hop C, Evers R, et al. (2016) Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics. Clin Pharmacol Ther 100:362–370.
    1. Sadeque AJ, Usmani KA, Palamar S, Cerny MA, Chen WG. (2012) Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin. Drug Metab Dispos 40:772–778.
    1. Schulze JJ, Lundmark J, Garle M, Skilving I, Ekström L, Rane A. (2008) Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 93:2500–2506.
    1. Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, et al. (2015) Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med 7:269ra2.
    1. Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, et al. (2016) Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 16:375–387.
    1. Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P. (2010) Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics 20:575–585.
    1. Swanson C, Mellström D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren O, Smith U, Eriksson AL, et al. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab 92:4878–4882.
    1. Tanner JA, Prasad B, Claw KG, Stapleton P, Chaudhry A, Schuetz EG, Thummel KE, Tyndale RF. (2017) Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and nongenetic factors. J Pharmacol Exp Ther 360:129–139.
    1. Urano T, Usui T, Shiraki M, Ouchi Y, Inoue S. (2009) Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density. Geriatr Gerontol Int 9:235–241.
    1. Verreault M, Kaeding J, Caron P, Trottier J, Grosse L, Houssin E, Pâquet S, Perreault M, Barbier O. (2010) Regulation of endobiotics glucuronidation by ligand-activated transcription factors: physiological function and therapeutic potential. Drug Metab Rev 42:110–122.
    1. Vrana M, Whittington D, Nautiyal V, Prasad B. (2017) Database of optimized proteomic quantitative methods for human drug disposition-related proteins for applications in physiologically based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 6:267–276.
    1. Wang YH, Trucksis M, McElwee JJ, Wong PH, Maciolek C, Thompson CD, Prueksaritanont T, Garrett GC, Declercq R, Vets E, et al. (2012) UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther 92:96–102.
    1. Wijayakumara DD, Hu DG, Meech R, McKinnon RA, Mackenzie PI. (2015) Regulation of human UGT2B15 and UGT2B17 by miR-376c in prostate cancer cell lines. J Pharmacol Exp Ther 354:417–425.
    1. Wong NS, Seah EZh, Wang LZ, Yeo WL, Yap HL, Chuah B, Lim YW, Ang PC, Tai BC, Lim R, et al. (2011) Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet Genomics 21:760–768.
    1. Yuan LM, Gao ZZ, Sun HY, Qian SN, Xiao YS, Sun LL, Zeng S. (2016) Inter-isoform hetero-dimerization of human UDP-glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and impacts on glucuronidation activity. Sci Rep 6:34450.
    1. Zhu AZ, Cox LS, Ahluwalia JS, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF. (2015) Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males. Pharmacogenet Genomics 25:263–269.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever